SPACInsider Logo
New IPO Filing: Churchill Capital Corp. Files for $400 Million SPAC
by Kristi Marvin on 2018-08-20 at 10:43am

Churchill Capital Corp. filed for a $400 million IPO very late Friday evening, with a focus on the technology and software sectors. Churchill is being led by Jerre Stead, as CEO and Director, and Michael Klein, as Chairman. This SPAC team has quite a few impressive names, from top to bottom.

In addition to Mr. Stead, who is the former Chairman and CEO of IHS Markit Ltd. (Nasdaq:INFO), and Mr. Klein, who is currently a Director of Credit Suisse and the Founder and Managing Partner of M. Klein and Company, the team includes a former member of President Barack Obama’s Cabinet (Karen Mills) and former Chairman of British Airways (Sir Martin Broughton).  You can read the team’s full bios here.

This is another big SPAC from Citigroup on the heels of the $552 million Spartan Energy Acquisition Corp.  However, given that Michael Klein is a Director of Credit Suisse, it’s surprising Credit Suisse is not an underwriter. Maybe they will be added at a later date or maybe there’s a conflict of interest I’m missing, but the absence was noted.

As far as structure, Churchill follows the typical Tier-1 structures found on the NYSE, except, instead of one-third of one warrant, the unit will be offering one-half of one warrant.  The sponsor, which is an affiliate of M. Klein and Company, will be purchasing 12,500,000 warrants at $1.00 for total at-risk capital of $12.5 million (before over-allotment). Full summary of terms below.

Churchill Capital Corp. Summary of Terms:
  • Focus:  Technology / Software
  • Size: $400 million
  • 100% held in trust ($10.00 per share)
  • $10.00 unit comprised of one share of Class A Common Stock + 1/2 of one Warrant 
  • Warrant call for redemption threshold: equals or exceeds $18.00 (cash or cashless exercise)
  • 24 months to complete an acquisition 
  • Limitation on Redemption Rights: 15%
  • At-risk Capital: $12.5 million (12,500,000 warrants at $1.00)
  • Underwriter fees: 2.0% + 3.5% deferred. 

Citigroup is sole book-runner.

Paul, Weiss, Rifkind, Wharton & Garrison LLP and Winston & Strawn LLP are Issuer’s Counsel and Underwriter’s Counsel, respectively.

 

Recent Posts
by Kristi Marvin on 2023-03-25 at 12:14pm

Terms Tracker for the Week Ending March 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. While this week was relatively quiet on the filings front, we did see March’s second SPAC IPO price with Oak Woods Acquisition Corp’s $50 million...

by Marlena Haddad on 2023-03-24 at 5:40pm

Latest Non-Redemption Agreements: ExcelFin Acquisition Corp. ExcelFin Acquisition Corp. (XFIN) Adds Non-Redemption Agreement In connection with the special meeting of stockholders of ExcelFin Acquisition Corp. (NASDAQ:XFIN) to extend its completion deadline from April 25, 2023 to October 25, 2023, the company and its sponsor, ExcelFin SPAC LLC, entered into a non-redemption agreement with an unaffiliated third party....

by Marlena Haddad on 2023-03-24 at 11:33am

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News:  Momentus SPAC backers accused of deliberately engineering a catastrophic deal  Momentus SPAC Backers Accused of Hiding Disastrous Deal’s Flaws A Momentus Inc. (NASDAQ:MNTS) investor sued backers of its blank-check merger with a shell company,...

by Nicholas Alan Clayton on 2023-03-24 at 7:20am

DiamondHead Holdings Corp. (NASDAQ:DHHC) announced in an 8-K this morning that its shareholders approved its combination with Great Southern Homes at a special meeting March 23. Only 109,426 shares were redeemed in the connection with the vote, but DiamondHead has seen about 87% redemptions in total across all previous votes, leaving it with about $43.9...

by Nicholas Alan Clayton on 2023-03-24 at 7:05am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen. This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a...

Privacy Policy|Terms Of Use
Copyright © 2023 SPACInsider, Inc. All Rights Reserved